Welcome : Guest

Personalizing Cancer Drugs Trends

Abstract

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception. Mechanisms responsible for driving cancer continue to emerge in diverse environments. In addition, the report presents an overview on the mechanism instrumental for causing some forms of breast cancer may also be responsible for promoting a subset of melanoma or brain cancer. The improved knowledge of cancer genetics is facilitating development of numerous drugs that target specific cancer cells. Cancer is one of the major chronic diseases worldwide and also the chief cause behind a huge number of fatalities. Each year, statistics post a larger figure than the previous year, indicating the rapidly growing incidence and prevalence of cancer. However, a similar pace of growth is not being reported in the area of development of drugs and therapies for treating cancers.

The report also predicts that the future holds immense promise for molecular analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with cancer treatment. Continued advances in technology are expected to lead to application of molecular analysis at each and every step in the course of cancer, ultimately enabling designing of optimal therapies, with the potential of achieving the best possible outcome, for individual patients.

Code: 141065
Price: $1450
Companies : 3
Pages: 28
Date: January, 2014
Market Data Tables : -

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Personalized Medicine in Cancer Treatment - An Overview......1
Molecular Diagnosis and Personalized Medicine Fast Gaining Ground......1
Advances in Personalized Medicine in Cancer......2
Research for Developing Tools for Genetic Profile of Tumors......3
Role of Pharmacogenomics in Personalized Therapies for Cancer......3
Modern Personalized Medicine for Cancer - A Notch above Traditional Variant......4
Genomic, Proteomic, Epigenomic and Metabolomic Information to Aid Personalized Medicine in Cancer......4
Genomic Information for Improving Efficacy of Personalized Medicine in Cancer......4
Importance of Proteomic Information in Personalized Medicine for Cancer......5
Study of Human Epigenome Contributing to Personalized Medicine for Cancer......5
Metabolomics - The Latest Addition to Personalized Medicine Domain......5
Personalized Medicine in Diagnosis and Treatment of Breast Cancer......6
Growing Trend towards Personalized Medicine to Fuel the Market for Cancer Diagnostics......7
Progressing Personalized Medicine Cancer Drugs to Clinical Stage......7
Need for Personalized Therapy to Go Beyond Primary Cancers......8
Regional Differences in Cancer Causative Factors - A Major Hindrance in Development of Cancer Therapies......8
Personalized Medicine in Cancer - Issues to Address......9
Insurance Coverage for Personalized Medicine......9
Participation of Healthcare Providers Key for Success of Personalized Medicine......9
Elimination of Regulatory Hindrances a Must......9
Increasing Awareness among Public for Maximizing Benefit......9
Scientific Barriers to Address......10
Recent Progress in Research......10
ALK Gene Inhibitors Foray into Pediatric Personalized Medicine......11
Biomarkers for Cancer......12
Early Detection Biomarkers......12
Diagnostic Biomarkers......12
Prognostic Biomarkers......12
Predictive Biomarkers......12
Pharmacodynamic Biomarkers......12
Biomarkers - Diagnosis and Prediction of Common Cancers......13
Breast Cancer......13
Lymphoma......13
Colon Cancer......13
Leukemia......13
Melanoma......13
Lung Cancer......14
An Introduction to Personalized Medicine......15
Uniqueness of DNA and Lifestyles Necessitate Personalized Medicine......15
Understanding Genetic Variations for Developing Better Drugs and Therapies......15
Molecular Analysis for Identification of Disease Sub-Groups in Polygenic Disorders......16
Key Benefits of Molecular Analysis of Diseases......16
Early Interventions and Enhanced Diagnoses......17
Improved Drug Development Efficiency......17
More Efficient Therapies......17
Personalized Medicine - Implications Involved......17
A Perfect Intellectual Property Rights System......17
Suitable Reimbursement Policies......18
Regulatory Reviews......18
Addressing Issues of Confidentiality, Privacy and Rights of Patients......18
Future Potential of Personalized Medicine......18
Cell Therapeutics, Inc. (USA)......20
F. Hoffmann-La Roche Ltd. (Switzerland)......20
H3 Biomedicine, Inc. (USA)......20
Roche Announces FDA Approval for Perjeta™......21
Roche Receives EU Consent for Zelboraf Cancer Drug......21
Roche Receives FDA Approval for Zelboraf Cancer Drug......22
Roche Obtains EU Approval for Tarceva......22
Pfizer Canada Launches XALKORI®......23
bioTheranostics Introduces New Line of “PRECIS” Biomarkers Series......23
AlacrisTheranostics Inks Pact with GlaxoSmithKline......24
4SC Discovery Obtains Grant for Developing New Personalized Cancer Drugs......24
Merrimack Enters into a Partnership with CTCA......25
Genomic Health Forms Strategic Alliance with OncoMed......25
Epizyme Enters into Partnership with Celgene for Advancing MLL Therapy......25
Abbott Expands Personalized Medicine Alliance with GSK......26
QIAGEN Inks Pact with Pfizer for Developing Companion Diagnostic......26
Blueprint Plans to Create Genomics-based Cancer Drugs......27
H3 Biomedicine Commences R&D Operations for Innovative Cancer Treatments......27
H3 Biomedicine Receives Research Funding from Eisai......28